Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg Compared to Placebo for Relief of Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) After 4 Weeks and to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg for Relief of Heartburn in Subjects With NERD After 6 Months

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg Compared to Placebo for Relief of Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) After 4 Weeks and to Evaluate the Efficacy and Safety of Vonoprazan 10 and 20 mg for Relief of Heartburn in Subjects With NERD After 6 Months

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonoprazan (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Registrational; Therapeutic Use
  • Acronyms PHALCON-NERD; PHALCON-NERD-301
  • Sponsors Phathom Pharmaceuticals

Most Recent Events

  • 25 Oct 2025 Results from the trial published in the American Journal of Gastroenterology.
  • 25 Oct 2025 Results presented in the Phathom Pharmaceuticals media release.
  • 07 Nov 2024 According to a Phathom Pharmaceuticals media release, an exploratory analysis from Phathom's Phase 3 Non-Erosive GERD study assessing the common yet infrequently evaluated nocturnal symptoms among Non-Erosive GERD patients, was presented in a poster presentation recognized with ACG's prestigious Presidential Poster Award, at the American College of Gastroenterology (ACG) 2024 Annual Meeting, held October 25-30 in Philadelphia, PA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top